Antiphospholipid antibodies and thrombosis: main details of articles found
| Reference . | No. of patients and enrollment criteria . | No. of controls . | Tests for lupus anticoagulants . | Anticardiolipin isotypes and cutoffs . |
|---|---|---|---|---|
| Case-control studies | ||||
| Finazzi et al14 | 70, cerebral stroke | 140 | aPTT, KCT, dRVVT, PL neutralization | > 10 GPL/MPL (ie, > 5 SD) |
| Barbui et al15 | 76, deep vein thrombosis | 190 | aPTT, KCT, dRVVT, PL neutralization | > 10 GPL/MPL (ie, > 5 SD) |
| Stegnar et al16 | 118, deep vein thrombosis | 147 | Not done | G, M > 4 SD |
| Hess et al17 | 110, cerebral stroke | 122 | Not done | > 10 GPL/MPL |
| Ginsburg et al18 | 100, cerebral stroke | 100 | Not done | > 1 GPL |
| Ginsburg et al18 | 90, deep vein thrombosis | 90 | Not done | > 1 GPL |
| APASS Group19 | 248, cerebral stroke | 255 | Not done | > 10 GPL/MPL |
| Camerlingo et al20 | 100, cerebral stroke | 100 | Not done | ≥ 10 GPL |
| Vaarala et al21 | 133, myocardial infarction | 133 | Not done | G, tertile and quartile |
| Zuckerman et al22 | 124, myocardial infarction | 76 | Not done | > 10 GPL, 8 MPL (ie, > 2 SD) |
| Wu et al23 | 119, myocardial infarction | 138 | Not done | G, M, A (> 2 SD) |
| Tuhrim et al24 | 524, cerebral stroke | 1024 | Not done | ≥ 23 GPL, ≥ 11 MPL |
| Cross-sectional studies | ||||
| Bongard et al25 | 107, deep vein thrombosis | 186 | Not done | > 5 GPL, > 3 MPL |
| Simioni et al26 | 59, deep vein thrombosis | 117 | Not specified | Not done |
| Oger et al27 | 110, deep vein thrombosis | 98 | Not done | G, M > 95th percentile |
| Ambispective studies | ||||
| Nencini et al28 | 55, cerebral stroke | 56 | TTI | > 20 GPL/MPL |
| Ginsberg et al29 | 65, deep vein thrombosis | 179 | aPTT, dRVVT, DPT, HexII PE | 30 GPL (ie, > 3 SD) |
| Prospective studies | ||||
| Levine et al30 | 81, anticardiolipin-positive and cerebral stroke | — | aPTT, KCT, dRVVT, TTI, PNP | > 10 GPL or > 7.5 MPL |
| Abu-Shakra et al31 | 390, systemic lupus erythematosus | — | aPTT | > 24 GPL |
| Prandoni et al32 | 21, lupus anticoagulants-positive and deep vein thrombosis | — | Not specified | Not specified |
| Finazzi et al33 | 360, antiphospholipid-positive | — | aPTT, KCT, dRVVT, TTI, PNP | > 10 GPL/MPL |
| Petri et al34 | 337, systemic lupus erythematosus | — | dRVVT, RCT | G, not specified |
| Levine et al35 | 132, anticardiolipin-positive and cerebral stroke | — | Not done | > 10 GPL |
| Rance et al36 | 153, deep vein thrombosis | — | Not specified | Not specified |
| Schulman et al37 | 412, deep vein thrombosis | — | Not done | > 5 GPL |
| De Bandt et al38 | 90, systemic lupus erythematosus | — | aPTT, Rossner index, PL neutralization | > 25 GPL (ie, 3 SD) |
| Reference . | No. of patients and enrollment criteria . | No. of controls . | Tests for lupus anticoagulants . | Anticardiolipin isotypes and cutoffs . |
|---|---|---|---|---|
| Case-control studies | ||||
| Finazzi et al14 | 70, cerebral stroke | 140 | aPTT, KCT, dRVVT, PL neutralization | > 10 GPL/MPL (ie, > 5 SD) |
| Barbui et al15 | 76, deep vein thrombosis | 190 | aPTT, KCT, dRVVT, PL neutralization | > 10 GPL/MPL (ie, > 5 SD) |
| Stegnar et al16 | 118, deep vein thrombosis | 147 | Not done | G, M > 4 SD |
| Hess et al17 | 110, cerebral stroke | 122 | Not done | > 10 GPL/MPL |
| Ginsburg et al18 | 100, cerebral stroke | 100 | Not done | > 1 GPL |
| Ginsburg et al18 | 90, deep vein thrombosis | 90 | Not done | > 1 GPL |
| APASS Group19 | 248, cerebral stroke | 255 | Not done | > 10 GPL/MPL |
| Camerlingo et al20 | 100, cerebral stroke | 100 | Not done | ≥ 10 GPL |
| Vaarala et al21 | 133, myocardial infarction | 133 | Not done | G, tertile and quartile |
| Zuckerman et al22 | 124, myocardial infarction | 76 | Not done | > 10 GPL, 8 MPL (ie, > 2 SD) |
| Wu et al23 | 119, myocardial infarction | 138 | Not done | G, M, A (> 2 SD) |
| Tuhrim et al24 | 524, cerebral stroke | 1024 | Not done | ≥ 23 GPL, ≥ 11 MPL |
| Cross-sectional studies | ||||
| Bongard et al25 | 107, deep vein thrombosis | 186 | Not done | > 5 GPL, > 3 MPL |
| Simioni et al26 | 59, deep vein thrombosis | 117 | Not specified | Not done |
| Oger et al27 | 110, deep vein thrombosis | 98 | Not done | G, M > 95th percentile |
| Ambispective studies | ||||
| Nencini et al28 | 55, cerebral stroke | 56 | TTI | > 20 GPL/MPL |
| Ginsberg et al29 | 65, deep vein thrombosis | 179 | aPTT, dRVVT, DPT, HexII PE | 30 GPL (ie, > 3 SD) |
| Prospective studies | ||||
| Levine et al30 | 81, anticardiolipin-positive and cerebral stroke | — | aPTT, KCT, dRVVT, TTI, PNP | > 10 GPL or > 7.5 MPL |
| Abu-Shakra et al31 | 390, systemic lupus erythematosus | — | aPTT | > 24 GPL |
| Prandoni et al32 | 21, lupus anticoagulants-positive and deep vein thrombosis | — | Not specified | Not specified |
| Finazzi et al33 | 360, antiphospholipid-positive | — | aPTT, KCT, dRVVT, TTI, PNP | > 10 GPL/MPL |
| Petri et al34 | 337, systemic lupus erythematosus | — | dRVVT, RCT | G, not specified |
| Levine et al35 | 132, anticardiolipin-positive and cerebral stroke | — | Not done | > 10 GPL |
| Rance et al36 | 153, deep vein thrombosis | — | Not specified | Not specified |
| Schulman et al37 | 412, deep vein thrombosis | — | Not done | > 5 GPL |
| De Bandt et al38 | 90, systemic lupus erythematosus | — | aPTT, Rossner index, PL neutralization | > 25 GPL (ie, 3 SD) |
aPTT indicates activated partial thromboplastin time; KCT, kaolin clotting time; dRVVT, dilute Russell viper venom time; PL neutralization, phospholipid neutralization test; TTI, tissue thromboplastin inhibition test; DPT, dilute prothrombin time; HexII PE, aPTT with hexagonal II phase phosphatidylethanolamine; PNP, platelet neutralization procedure; and RCT, recalcification time.